If you've been searching for a dependable Lidocaine Base manufacturer, you've probably noticed how many suppliers make big claims but fall short on consistency. Alex Pharmachem Pvt. Ltd. has been in this business for over 24 years now, and Lidocaine Base happens to be one of the products the company is genuinely known for — not just another SKU on a long catalog.
Lidocaine Base is a free base local anesthetic and antiarrhythmic drug, and it plays a fairly important role in modern pharmaceutical formulations. It's used to prevent and manage pain during surgical or diagnostic procedures, and it also finds application in treating cardiac arrhythmias. What makes it versatile is the way it can be administered — orally, topically, or as an injectable solution — which is why so many downstream formulators rely on a steady, high-purity supply.
Manufactured in the company’s facility which complies with the WHO GMP in Ankleshwar, Gujarat (the Ankleshwar region is home to one of the biggest chemical industrial centers in Asia), Lidocaine Base is manufactured along with its counterpart Lidocaine HCL, with a total annual manufacturing capacity of 180 MT. This speaks volumes about the significance of this product range for the company.
| Parameter | Detail |
|---|---|
| Product Name | Lidocaine Base |
| CAS Number | 137-58-6 |
| Therapeutic Category | Local Anesthetic & Antiarrhythmic API |
| Physical Description | White Crystalline Powder |
| Pharmacopeial Specifications | IP, BP, EP, USP |
| Annual Production Capacity | 180 MT (Combined Lidocaine Range) |
| Regulatory Status | WHO-GMP, Written Confirmation (WC), Local FDA, HALAL, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ZED Gold (MSME), Open & Closed Part DMF |
| Packing Options | 25 Kg Fiber Drum, 50 Kg HDPE Drum |
| Manufacturing Location | Ankleshwar, Gujarat, India (G.I.D.C. Industrial Estate) |
| Plant Type | Dedicated WHO-GMP Compliant Facility |
Alex Pharmachem currently serves 500+ customers spread across more than 55 countries, and Lidocaine Base is one of the flagship products moving through that network. Demand has been picking up steadily in regions where local pharmaceutical manufacturing is expanding and API sourcing standards are tightening.